Compass Other Current Assets from 2010 to 2025

CMPX Stock  USD 2.10  0.06  2.94%   
Compass Therapeutics Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets will likely drop to about 3.7 M in 2025. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2019-12-31
Previous Quarter
5.7 M
Current Value
M
Quarterly Volatility
2.3 M
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 7.7 M or Interest Income of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.26. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of Compass Therapeutics over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Compass Therapeutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

Compass Other Current Assets Regression Statistics

Arithmetic Mean2,395,619
Geometric Mean1,917,931
Coefficient Of Variation84.56
Mean Deviation1,458,351
Median1,370,000
Standard Deviation2,025,724
Sample Variance4.1T
Range7.2M
R-Value0.60
Mean Square Error2.8T
R-Squared0.36
Significance0.01
Slope255,368
Total Sum of Squares61.6T

Compass Other Current Assets History

20253.7 M
2024M
20231.4 M
20228.2 M
20212.6 M
20203.1 M
2019935 K

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current AssetsM3.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.